Fritextsökning
Innehållstyper
-
The dock that “thinks” for itself
The world of bulk material handling seems straightforward at first glance: moving, filling, delivering. However, the art of dealing with a variety of different ...
-
Marie Gårdmark: New incentives for orphan products on its way
"Let’s hope that the learnings from development of new therapies for rare diseases will spill over to more common conditions, orphan products paving the wave fo...
-
BioVentureHub CEO: “Companies with a high degree of interaction achieve greater success”
he also highlights a study that points out that companies with a high degree of interaction with other companies achieve greater success.
-
Anna Törner: To kill your darlings
Hopes were high when Anna Törner and her colleague started a study on a dietary supplement that seemed unbelievably good. “Enthusiastically, we dreamed of excit...
-
Nordic Regulatory experts: Improving biotech chances of Succ
Why is it that so many biotech companies fail? And what are the tools needed to change that fact?
-
The stomach medication that became the biggest blockbuster of the 1990s
The omeprazole molecule was synthesised as early as 1979, but it took many years before the then Astra had an approved pharmaceutical. Once this happened, a tab...
-
Tio minuters trädgårdsarbete räcker
Så lite som tio minuters motion per vecka ser ut att minska risken för hjärtdöd, enligt en kinesisk observationsstudie.
-
Forskning kring skräddarsydd behandling av kronisk myeloisk leukemi prisas
Forskare vid Lunds och Helsingfors universitet får 2019 års stipendium på 20 000 US-dollar från företaget Incyte för hematologisk forskning inom kronisk myeloisk leukemi.
-
Ett steg närmare ett medel mot åldrande
Med en ny metod kan KI-forskarna ha hittat ett nytt medel mot åldrande.
-
Combining two drug delivery strategies to improve bioavailability
Danish researchers hope to increase the bioavailability of low solubility drugs.
-
Orexo vinner långdragen patenttvist
Amerikanska domstolen för överklagande slår fast att bolagets långa patent för Zubsolv är giltigt. Tidigare beslut som förklarade patentet ogiltigt rivs alltså upp.
-
MVA:s CEO: “Our investments should improve people´s everyday lives”
Involuntary infertility and diabetes are two of the areas on the agenda of the Medicon Valley Alliance.
-
Before you choose a CRO
– We are a small company and it is very important for us to maintain our core competence within development of novel nanomaterials, Tove Sivik Sonne, Head of De...
-
New map of eye proteins
A new mapping of proteins in the eye opens the door for new treatments of eye diseases in the future.
-
Column: Repurposing as a golden ticket to approval
"Hopefully, in the end, patients will be winners by receiving on-label treatments for which benefit-risk has been properly assessed." In a column Marie Gårdmark...
-
CAR-T therapies give continued hope: “Almost half of the patients have become disease-free”
When the first CAR-T therapies appeared, hopes were raised for the effective treatment for critically ill cancer patients. After a somewhat sluggish start, abou...
-
Spetsteknologi utvecklad i samarbete med forskare – framgångsrecept på vägen till nya läkemedel
Varje år analyserar forskare från hela världen miljontals molekyler för att identifiera nya potentiella läkemedel. I tre decennier har Biacore™ ytplasmonresonan...
-
Svensk vd till Mercks styrelse
Han är svensken som tagit sig till toppen i 3M-koncernen. Nu tar han plats i Mercks styrelse.
-
De får det svenska storpriset
Cancerforskare får en miljon dollar i prissumma.
-
Marie Gårdmark: Do EMA and FDA talk to each other?
Of course they do! The collaboration started already in 2003, writes Marie Gårdmark in a column.
-
Coordination of world-class research facilities
Four unique world-class research facilities are located just a few hours apart. Properly utilised, a Nordic centre for world-leading life science innovation and...
-
Astrazeneca får godkänt för cancerläkemedel
Nu är det klart att FDA godkänner Astrazenecas läkemedel Imfinzi, för behandling mot cancer i urinblåsan.
-
Engage with your CMO early
Gordon Hutton is Materials Science Lead at Thermo Fisher Scientific’s, formerly GSK, small molecule API site in Cork, Ireland.
-
Danish biorefinery can save US billions
The Danish Inbicon biorefinery process could save the US billions on foreign oil, the organization states.
BREAKING